心血管疾病——聚焦动脉粥样硬化、其预防、并发症以及治疗的最新进展。
Cardiovascular Diseases-A Focus on Atherosclerosis, Its Prophylaxis, Complications and Recent Advancements in Therapies.
机构信息
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medykow 18, 40-752 Katowice, Poland.
出版信息
Int J Mol Sci. 2022 Apr 23;23(9):4695. doi: 10.3390/ijms23094695.
Abstract
Long-term consequences of atherosclerosis remain the major culprit of mortality in developed and developing countries [...].
摘要
动脉粥样硬化的长期后果仍然是发达国家和发展中国家死亡率的主要罪魁祸首[...]。
相似文献
1
Cardiovascular Diseases-A Focus on Atherosclerosis, Its Prophylaxis, Complications and Recent Advancements in Therapies.心血管疾病——聚焦动脉粥样硬化、其预防、并发症以及治疗的最新进展。
Int J Mol Sci. 2022 Apr 23;23(9):4695. doi: 10.3390/ijms23094695.
2
Update on RAAS Modulation for the Treatment of Diabetic Cardiovascular Disease.糖尿病心血管疾病治疗中 RAAS 调节的最新进展。
J Diabetes Res. 2016;2016:8917578. doi: 10.1155/2016/8917578. Epub 2016 Aug 29.
3
[Roles of angiopoietin-like protein 2 (Angptl2) in chronic inflammation and atherosclerotic diseases].血管生成素样蛋白2（Angptl2）在慢性炎症和动脉粥样硬化疾病中的作用
Nihon Rinsho. 2011 Jan;69(1):163-7.
4
The pathophysiology of cardiovascular disease in diabetes mellitus and the future of therapy.糖尿病中心血管疾病的病理生理学与治疗前景
J Cardiometab Syndr. 2007 Spring;2(2):108-13. doi: 10.1111/j.1559-4564.2007.06046.x.
5
Evaluating periodontal risk for patients at risk of or suffering from atherosclerosis: recent biological hypotheses and therapeutic consequences.评估有或患有动脉粥样硬化风险的患者的牙周病风险：最近的生物学假说和治疗后果。
Arch Cardiovasc Dis. 2011 May;104(5):352-8. doi: 10.1016/j.acvd.2011.02.002. Epub 2011 May 11.
6
HDL-cholesterol: is it really good? Differences between apoA-I and HDL.高密度脂蛋白胆固醇：它真的有益吗？载脂蛋白A-I与高密度脂蛋白之间的差异。
Biochem Pharmacol. 2008 Aug 15;76(4):443-52. doi: 10.1016/j.bcp.2008.04.020. Epub 2008 May 8.
7
Residual cardiovascular risk among people with diabetes.糖尿病患者的残余心血管风险。
Diabetes Obes Metab. 2019 Apr;21 Suppl 1:28-38. doi: 10.1111/dom.13646.
8
Cardiorenal consequences of atherosclerosis and statins therapy: from the past to the future.动脉粥样硬化和他汀类药物治疗的心脏肾脏后果：从过去到未来
Curr Pharm Des. 2005;11(30):3973-84. doi: 10.2174/138161205774580589.
9
Cardiovascular risk factors in inflammatory arthritis.炎症性关节炎的心血管危险因素。
Curr Opin Lipidol. 2011 Aug;22(4):296-301. doi: 10.1097/MOL.0b013e3283488c50.
10
[Not Available].[无可用内容]
Clin Investig Arterioscler. 2016 May;28 Suppl 2:1-2. doi: 10.1016/S0214-9168(16)30163-2.
引用本文的文献
1
Microbiome and cardiovascular health unexplored frontiers in precision cardiology: a narrative review.微生物群与心血管健康：精准心脏病学中未被探索的前沿领域：一篇综述。
Ann Med Surg (Lond). 2025 May 26;87(7):4255-4261. doi: 10.1097/MS9.0000000000003430. eCollection 2025 Jul.
2
HIIT and MICT mitigate endothelial dysfunction in early atherosclerotic mice via PCSK9 inhibition.高强度间歇训练（HIIT）和中等强度持续训练（MICT）通过抑制前蛋白转化酶枯草溶菌素9（PCSK9）减轻早期动脉粥样硬化小鼠的内皮功能障碍。
Sci Rep. 2025 Aug 19;15(1):30411. doi: 10.1038/s41598-025-05206-7.
3
Fraxin Alleviates Atherosclerosis by Inhibiting Oxidative Stress and Inflammatory Responses via the TLR4/PI3K/Akt Pathway.秦皮通过TLR4/PI3K/Akt途径抑制氧化应激和炎症反应减轻动脉粥样硬化。
Curr Issues Mol Biol. 2025 Apr 27;47(5):308. doi: 10.3390/cimb47050308.
4
Uncovering the oxidative stress and hematological consequences of chronic cobalt exposure on atherosclerosis.揭示慢性钴暴露对动脉粥样硬化的氧化应激和血液学影响。
Biometals. 2025 Jul 15. doi: 10.1007/s10534-025-00722-5.
5
Inflammatory indices AISI and SIRI in atherosclerosis risk stratification: validation across community and intensive care populations.炎症指标AISI和SIRI在动脉粥样硬化风险分层中的作用：在社区和重症监护人群中的验证
Ann Med. 2025 Dec;57(1):2530792. doi: 10.1080/07853890.2025.2530792. Epub 2025 Jul 13.
6
Clinical Application of Traditional Chinese Medicine Nursing Care in Cardiovascular Patients.中医护理在心血管疾病患者中的临床应用
Anatol J Cardiol. 2025 Jul 8;29(8):394-400. doi: 10.14744/AnatolJCardiol.2025.5091.
7
Synergistic effects of notoginsenoside R1 and saikosaponin B2 in atherosclerosis: A novel approach targeting PI3K/AKT/mTOR pathway and macrophage autophagy.三七皂苷R1和柴胡皂苷B2在动脉粥样硬化中的协同作用：一种靶向PI3K/AKT/mTOR通路和巨噬细胞自噬的新方法。
PLoS One. 2025 Jun 27;20(6):e0326687. doi: 10.1371/journal.pone.0326687. eCollection 2025.
8
Clusterin ameliorates diabetic atherosclerosis by suppressing macrophage pyroptosis and activation.聚集素通过抑制巨噬细胞焦亡和激活来改善糖尿病性动脉粥样硬化。
Front Pharmacol. 2025 Apr 23;16:1536132. doi: 10.3389/fphar.2025.1536132. eCollection 2025.
9
The non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio and its combination with obesity indicators as a predictor of all cause and cardiovascular mortality in non-diabetic individuals.非高密度脂蛋白胆固醇与高密度脂蛋白胆固醇之比及其与肥胖指标的组合作为非糖尿病个体全因死亡率和心血管死亡率的预测指标。
BMC Public Health. 2025 Apr 23;25(1):1513. doi: 10.1186/s12889-025-22789-y.
10
Comprehensive analysis of risk factors for intracranial aneurysm rupture: a retrospective cohort study.颅内动脉瘤破裂危险因素的综合分析：一项回顾性队列研究。
Front Neurol. 2025 Mar 31;16:1559484. doi: 10.3389/fneur.2025.1559484. eCollection 2025.
本文引用的文献
1
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.2022年美国心脏协会/美国心脏病学会/美国心力衰竭学会心力衰竭管理指南：执行摘要：美国心脏病学会/美国心脏协会临床实践指南联合委员会报告
Circulation. 2022 May 3;145(18):e876-e894. doi: 10.1161/CIR.0000000000001062. Epub 2022 Apr 1.
2
The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia.喹唑啉类 Otaplimastat（SP-8203）可减少延迟 rtPA 诱导的溶栓后缺血性脑卒中的出血性转化和死亡率加重。
Int J Mol Sci. 2022 Jan 26;23(3):1403. doi: 10.3390/ijms23031403.
3
The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets.VEGF 家族在动脉粥样硬化发展中的作用及其作为治疗靶点的潜力。
Int J Mol Sci. 2022 Jan 15;23(2):931. doi: 10.3390/ijms23020931.
4
A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants.一种评估 PCSK9 变异体活性和分类的系统方法。
Int J Mol Sci. 2021 Dec 18;22(24):13602. doi: 10.3390/ijms222413602.
5
Emerging Anti-Atherosclerotic Therapies.新兴的抗动脉粥样硬化疗法。
Int J Mol Sci. 2021 Nov 9;22(22):12109. doi: 10.3390/ijms222212109.
6
Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases.肥胖的病理生理分子机制：MAFLD 和 NASH 与心血管疾病的联系。
Int J Mol Sci. 2021 Oct 27;22(21):11629. doi: 10.3390/ijms222111629.
7
Inhibition of Atherosclerosis and Liver Steatosis by Agmatine in Western Diet-Fed apoE-Knockout Mice Is Associated with Decrease in Hepatic De Novo Lipogenesis and Reduction in Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio.胍丁胺抑制西方饮食喂养的载脂蛋白 E 基因敲除小鼠动脉粥样硬化和肝脏脂肪变性与其减少肝脏从头合成脂质和降低血浆甘油三酯/高密度脂蛋白胆固醇比值有关。
Int J Mol Sci. 2021 Oct 1;22(19):10688. doi: 10.3390/ijms221910688.
8
Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress.SGLT-2 抑制剂恩格列净对遗传性高甘油三酯血症大鼠肝脏、肾脏和脂肪组织的复杂积极影响：可能通过减轻细胞衰老和氧化应激来实现。
Int J Mol Sci. 2021 Sep 30;22(19):10606. doi: 10.3390/ijms221910606.
9
Sex-Related Differences in Cardiovascular Disease Risk Profile in Children and Adolescents with Type 1 Diabetes.性别相关差异在 1 型糖尿病患儿和青少年心血管疾病风险特征中的表现。
Int J Mol Sci. 2021 Sep 22;22(19):10192. doi: 10.3390/ijms221910192.
10
Local Preirradiation of Infarcted Cardiac Tissue Substantially Enhances Cell Engraftment.局部预照射梗死心肌组织显著增强细胞移植。
Int J Mol Sci. 2021 Aug 24;22(17):9126. doi: 10.3390/ijms22179126.
Zotero 插件